
GBT
Healthcare · Biotechnology · $4.62B market cap
Latest report
Before the open
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Sep 30, 2022
EPS trend, 90 days to now · +3.6% over 90 days · 30-day revisions 0 up, 0 down
Beat estimates in 1 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Aug 8, 2022 | Before the open | -1.19 | -1.26 | -5.9% |
| May 4, 2022 | After the close | -1.31 | -1.26 | +3.8% |
| Feb 23, 2022 | After the close | -1.13 | -1.36 | -20.4% |
| Nov 4, 2021 | After the close | -1.11 | -1.13 | -1.8% |
| Aug 3, 2021 | After the close | -1.19 | -1.12 | +5.9% |
| May 5, 2021 | After the close | -1.01 | -1.21 | -19.8% |
| Feb 24, 2021 | After the close | -0.95 | -1.00 | -5.7% |
| Nov 5, 2020 | After the close | -0.73 | -0.97 | -32.1% |
| Aug 5, 2020 | After the close | -1.15 | -0.86 | +25.2% |
| May 6, 2020 | After the close | -1.51 | -1.20 | +20.5% |
| Feb 26, 2020 | After the close | -1.24 | -1.59 | -28.2% |
| Nov 7, 2019 | After the close | -1.05 | -1.07 | -1.9% |
| Aug 7, 2019 | After the close | -0.96 | -1.01 |
Global Blood Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities with sickle cell disease (SCD). The company offers Oxbryta tablets, an oral, once-daily therapy for SCD. It also evaluates the safety and pharmacokinetics of single and multiple doses of Oxbryta in a Phase II a clinical trial of adolescent and pediatric…
| -5.2% |
| May 8, 2019 | After the close | -0.94 | -0.87 | +7.4% |
| Feb 27, 2019 | After the close | -0.89 | -0.93 | -4.5% |
| Nov 6, 2018 | After the close | -0.86 | -0.83 | +3.5% |
| Aug 2, 2018 | After the close | -0.88 | -0.78 | +11.4% |
| May 7, 2018 | After the close | -0.91 | -0.87 | +4.4% |
| Feb 27, 2018 | After the close | -0.71 | -0.94 | -32.4% |